rofecoxib has been researched along with Prostatic Hyperplasia in 1 studies
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Silverio, F | 1 |
| Bosman, C | 1 |
| Salvatori, M | 1 |
| Albanesi, L | 1 |
| Proietti Pannunzi, L | 1 |
| Ciccariello, M | 1 |
| Cardi, A | 1 |
| Salvatori, G | 1 |
| Sciarra, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level[NCT01678313] | Phase 2 | 140 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Efficacy:~Change from Baseline in the International Prostate Symptom Score (IPSS) from baseline and 3 months The International Prostate Symptom Score (IPSS) is an 7 symptom questions including 4 voiding questions (IPSS Voiding), 3 storage questions (IPSS Storage) The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always.~Total IPSS score = IPSS voiding + IPSS Storage Rang = 0 to 35 (asymptomatic to very symptomatic). Mild = 0 to 7; Moderate = 8 to 19; Severe = 20 to 35~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 12.0 | 7.70 | -4.31 |
| Study Group | 13.1 | 6.45 | -6.63 |
"Efficacy:~Change from Baseline in the IPSS Storage from baseline and 3 months The IPSS subscore (IPSS Storage) is a 3 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Storage score can therefore range from 0 to 15 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 6.06 | 4.01 | -2.05 |
| Study Group | 5.59 | 3.09 | -2.5 |
"Efficacy:~Change from Baseline in the IPSS Voiding from baseline and 3 months. The IPSS subscore (IPSS Voiding) questionnaires is a 4 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Voiding score can therefore range from 0 to 20 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 5.54 | 3.45 | -2.09 |
| Study Group | 7.55 | 3.84 | -3.71 |
"Efficacy:~Change from Baseline in the maximum flow rate (Qmax) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | mL/s (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 10.0 | 11.9 | 1.9 |
| Study Group | 12.2 | 12.2 | -0.09 |
"Efficacy:~Change from Baseline in the serum PSA level from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 15.2 | 13.5 | -1.70 |
| Study Group | 10.8 | 9.42 | -1.43 |
"Efficacy:~Change from Baseline in the Void Volume (VV) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | mL (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 175 | 231 | 55.7 |
| Study Group | 259 | 227 | -32.3 |
1 trial available for rofecoxib and Prostatic Hyperplasia
| Article | Year |
|---|---|
Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
Topics: Aged; Aged, 80 and over; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Fi | 2005 |